Enliven Therapeutics Inc Com Gains 38.77%
Tue, Mar 19, 2024 at 07:28 PM
Enliven Therapeutics Inc Com (ELVN:NASDAQ) rocketted at $17.54, representing a gain of 38.8%. On Tue, Mar 19, 2024, ELVN:NASDAQ hit a New 2-Week High of $17.54. The stock appeared on our News Catalysts scanner on Tue, Mar 19, 2024 at 11:02 AM in the 'PRIVATE PLACEMENT' category. From Tue, Mar 05, 2024, the stock recorded 30.00% Up Days and 27.27% Green Days
About Enliven Therapeutics Inc Com (ELVN:NASDAQ)
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies.
Top 10 Gainers:
- Ontrak Inc. (OTRK:NASDAQ), 131.58%
- Fusion Pharmaceuticals Inc. (FUSN:NASDAQ), 99.06%
- SCWorx Corp. (WORX:NASDAQ), 53.51%
- Sarcos Technology and Robotics Corporation (STRC:NASDAQ), 40.38%
- Enliven Therapeutics Inc Com (ELVN:NASDAQ), 38.77%
- Puyi Inc. (PUYI:NASDAQ), 33.93%
- BitFuFu Inc. (FUFU:NASDAQ), 32.35%
- Critical Metals Corp. (CRML:NASDAQ), 31.04%
- Vincerx Pharma Inc. (VINC:NASDAQ), 28.31%
- Actinium Pharmaceuticals, Inc. (ATNM:NYSEMKT), 25.54%